Innovent Biologics (IVBXF) Expected to Announce Quarterly Earnings on Thursday

Innovent Biologics (OTCMKTS:IVBXF) is expected to be releasing its results before the market opens on Thursday, March 26th. Analysts expect Innovent Biologics to post earnings of $0.0172 per share and revenue of $985.8970 million for the quarter.

Innovent Biologics Price Performance

OTCMKTS:IVBXF opened at $10.77 on Thursday. Innovent Biologics has a 52-week low of $5.00 and a 52-week high of $15.12. The stock’s 50-day simple moving average is $10.78 and its 200 day simple moving average is $11.32.

Innovent Biologics Company Profile

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).